Tuberculosis (TB) is an airborne global pandemic that kills 1.6 million people each year and makes 10 million people sick. As an airborne bacterial pathogen, TB can infect anyone, but TB incidence is highest in low- and middle-income countries (LMICs). Poverty and its causes and effects, such as overcrowding and undernourishment, increase the risk of TB transmission and disease. The difficulty of diagnosing and successfully treating all people who have TB contributes significantly to antimicrobial resistance (AMR). TB also thrives in situations of displacement and social destabilization: humanitarian crises in countries with high (drug-resistant) TB burdens undermine provision of diagnostics, treatment, and prevention. Ukraine, for example, already had one of the world’s highest rates of drug-resistant TB before the Russian invasion. The conflict has undermined access to health services; increasing rates of TB infection and disease can reasonably be expected both in Ukraine and among the millions of people forced to flee.

Without further action, a projected 31.8 million TB deaths will occur by 2050, corresponding to an economic loss of US$17.5 trillion. Despite the huge threat posed by TB, political and financial support lags dangerously behind that of other communicable diseases. The world only spends half of the financial resources governments committed to mobilize for TB research at the 2018 United Nations High-Level Meeting on TB and one-fifth of what is now needed to deliver the transformative technologies required to end the TB pandemic by the Sustainable Development Goal (SDG) deadline of 2030.

New vaccines are needed to tackle this crisis. Vaccines that prevent TB disease would save millions of lives, avert billions of dollars in treatment costs, and help curb the threat of AMR. Developing new TB vaccines by 2030 is within reach if decision-makers prioritize TB vaccine R&D as a signature piece of global health and AMR agendas.

**Key takeaways**

1. TB is an airborne global pandemic that kills 1.6 million people each year, causes over 10 million people to fall sick and poses catastrophic costs for patients and rising costs for health systems.
2. TB R&D is severely underfunded relative to the threat TB poses.
3. Drug-resistant TB is a major contributor to the global burden of antimicrobial resistance (AMR) and a significant cause of AMR deaths.
4. Without immediate corrective action by governments—including through additional funding for innovation—TB will cost the global economy a cumulative US$17.5 trillion by 2050.
5. Every $1 invested in the development and rollout of new TB vaccines for adolescents and adults will return $7 to the global economy over 25 years.
6. New vaccines against TB offer one of the best tools for stopping the spread of drug-resistant TB, saving lives, and mitigating the economic impact of TB-related AMR.
7. Decision makers must prioritize funding for TB vaccine R&D within all AMR initiatives.

**Key terms**

- **Mycobacterium tuberculosis (Mtb)**: Mtb is a species of pathogenic bacteria and the causative agent of TB infection and disease.

- **Rifampicin-resistant TB (RR-TB)**: TB resistant to rifampicin, one of the most effective first-line anti-TB drugs.

- **Isoniazid-resistant TB (Hr-TB)**: TB resistant to isoniazid but susceptible to rifampicin.

- **Multidrug-resistant TB (MDR-TB)**: TB resistant to rifampicin and isoniazid.

- **Pre-XDR-TB**: TB that is resistant to rifampicin (and may also be resistant to isoniazid), and any fluoroquinolone drug agent (e.g., levofloxacin or moxifloxacin).

- **Extensively drug-resistant TB (XDR-TB)**: TB caused by Mtb strains that fulfil the definition of MDR/RR-TB and which are also resistant to any fluoroquinolone and at least one additional Group A drug (e.g., bedaquiline or linezolid).

- **Group A drugs**: The most potent group of drugs in the World Health Organization ranking of second-line medicines for the treatment of drug-resistant forms of TB.
Drug-resistant TB: A public health threat

Drug-resistant TB is an urgent global health problem. After remaining stable between 2015–2020, the number of new cases of MDR/RR-TB rose by 3% in 2021 to an estimated 450,000 people. This increase was driven by an overall increase in TB incidence due to setbacks to TB elimination caused by the COVID-19 pandemic. Current strategies to address drug-resistant TB are clearly inadequate:

• In 2021, almost half a million people (450,000) fell ill with drug-resistant forms of TB.
• Most people who develop drug-resistant TB receive neither diagnosis nor treatment: only 167,000 people were diagnosed with drug-resistant TB in 2021 and 162,000 people were started on treatment.
• Based on these figures, the WHO estimates that treatment coverage (i.e., the number of people enrolled on treatment as a percentage of the number of people who developed MDR/RR-TB) is only 36%.
• Without treatment, most people with drug-resistant TB will die. Globally in 2019 (the latest patient cohort for which data are available), the treatment success rate for MDR-TB/RR-TB with second-line regimens was 60%.

The majority of people who contract drug-resistant TB face catastrophic personal and health costs due to the duration, expense, and toxicity of treatment. Likewise, prevention and treatment of drug-resistant pathogens consumes large amounts of health resources worldwide, sometimes at the cost of national TB programs. Addressing drug-resistant TB through treatment alone is both costly and insufficient. New effective TB vaccines would make a major difference.

Treatment alone will not end drug-resistant TB

Drug-resistant TB treatment can last for months—or even years—with many debilitating and disabling side effects. Treating drug-resistant TB is very expensive for LMIC health systems (with current regimens costed at ≥US$ 1000 per person). In 2022, WHO recommended a shorter six-month regimen for people with confirmed MDR-TB/RR-TB. However, this regimen is not accessible to all who need it and side effects, though improved compared to older treatment options, can still be debilitating. Despite this dramatic improvement in the standard of care, treatment for drug-resistant TB remains lengthy and dependent on the efficacy of a limited number of antibiotics. TB caused by bacteria which do not respond to second-line anti-TB drugs can leave patients without any further treatment options. Extensively drug-resistant TB has very poor treatment outcomes.

By the end 2021, only 649,000 people (43%) of the UN target to treat 1.5 million people with MDR/RR-TB between 2018-2022 were reached.

High burden countries

The World Health Organization (WHO) identifies 30 high burden MDR-TB countries:

1. Angola
2. Azerbaijan
3. Bangladesh
4. Belarus
5. China
6. Democratic People’s Republic of Korea
7. Democratic Republic of Congo
8. Ethiopia
9. India
10. Indonesia
11. Kazakhstan
12. Kenya
13. Kyrgyzstan
14. Mozambique
15. Myanmar
16. Nigeria
17. Pakistan
18. Papua New Guinea
19. Peru
20. Philippines
21. Republic of Moldova
22. Russian Federation
23. Somalia
24. South Africa
25. Tajikistan
26. Thailand
27. Ukraine
28. Uzbekistan
29. Viet Nam
30. Zimbabwe
Developing resistance

Anti-TB medicines have been used for decades. Strains that resist one or more of the medicines have been documented in every country surveyed by the WHO. On average, 20% of the people with MDR/RR-TB also have resistance to a fluoroquinolone, a key second line antibiotic. ix Resistance is also developing to newer backbone medicines such as bedaquiline. ix Drug resistance emerges through simple mutation, incorrect prescription by health care providers, by use of poor-quality drugs, and when patients stop treatment prematurely, often due to the grueling nature of treatment regimens, insufficient treatment support, or interruptions to drug supply.

TB vaccines and AMR

Vaccination is one of the most effective ways to control and prevent AMR. Vaccines against bacterial pathogens—like those that prevent pneumonia and flu—have been very effective in reducing incidence of disease, use of antibiotics, and AMR, despite facing a number of hurdles to global access, implementation, and use. xiv,xvi,xvii Yet, the only available TB vaccine is the century-old Bacillus Calmette-Guérin (BCG) vaccine, which is mostly ineffective in adolescents and adults, who are most at risk of developing and spreading TB.

A future TB vaccine could significantly help control drug-resistant TB, in a cost effective and affordable way. xiv,xviii,xix By preventing TB, new vaccines would reduce the need for antibiotics, and thus reduce the development of drug resistance and onward transmission. A TB vaccine for infants could avert an estimated 2.4–8.6 million treatments (up to US$299 million in treatment costs saved), while one for adolescents and adults could avert 21.9–42.3 million treatments, saving up to US$3.2 billion in treatment costs. xx

Moreover, the mechanisms by which vaccines confer immunity are likely to differ from the mechanisms through which drug-resistance develops. Vaccines may also reduce the development of AMR in other pathogens exposed to antibiotics during TB treatment. Therapeutic vaccines, in combination with drugs, could reduce treatment duration, the risk of disease recurrence, and post-treatment health complications.

The cost of inaction wildly surpasses the cost of action. TB vaccines have been shown to be overwhelmingly cost-effective, particularly when targeted to adolescents and adults. Introduction of an adolescent/adult vaccine in most high drug-resistant TB burden countries could produce $283–474 billion in economic benefits by 2050. xix One study estimates that new TB vaccines could avert over a third of deaths attributable to bacterial AMR. xxi Countries can save up to 23.8 million lives and avert $13.1 trillion in economic losses if governments meet the WHO End TB targets by 2030. xx

TB vaccines neglected in the AMR agenda

TB is commonly overlooked in AMR R&D programs, including CARB-X,xxiv the world’s largest and most diverse portfolio of early development antibacterial projects. Supporting early development of antibiotics, vaccines, rapid diagnostics and other life-saving products, CARB-X addresses other threats identified as “Critical” or “High” in the WHO’s 2017 Priority Pathogen for R&D of new antibiotics list, but not TB. xxv The European Commission’s recent communication on the new EU global health strategy.xxvi does mention TB among its priorities for health equity, and the European One Health Action Plan against Antimicrobial Resistance (AMR)xxvi explicitly connects resistant strains of TB to AMR. However, the EU health security prevention and response agency, HERA, does not include TB research as part of the priority it places on health equity, and the 2023-2024 Horizon Europe workplan for Healthxxvii does not mention TB even once.

WHO calls for highest priority action on TB vaccines

In July 2022, WHO published an urgent call to use and develop new vaccines to tackle AMR, highlighting that the development of more effective vaccines against TB should be accelerated. xxi Given the urgent need, the WHO calls for the accelerated development of more effective vaccines against TB, with the highest level of ‘Priority 1: critical’ in the

India: the world’s highest TB burden

India accounted for 38% of global TB deaths among HIV-negative people and 34% of the combined total number of TB deaths in HIV-negative and HIV-positive people. With almost 28% of all TB infections and 26% of MDR/RR-TB cases globally in 2021, India faces the world’s highest burden of TB—and it is rising. xii Urgent action is needed to prevent a major health crisis caused by widespread misuse of antibiotics.

MDR/RR-TB incidence (2021): 119,000
In December 2022, WHO published an investment case presenting eight health and economic arguments for investing in new TB vaccines. Every $1 invested in the development and rollout of new TB vaccines for adolescents and adults will return $7 to the global economy over 25 years.³³

Funders, industry, governments, nongovernmental and supranational organizations, academic institutions, and researchers need to increase investments in TB vaccine R&D to address AMR globally. This includes creating new financing mechanisms for late-stage vaccine evaluation, vaccine introduction, manufacturing capacity development, and evaluation of new vaccine effectiveness and impact in real-world settings.

The potential of EU support for TB vaccine R&D

Europe’s One Health Action Plan against AMR calls on the European Union (EU) and its Member States (MS) to invest in “infection prevention and control in vulnerable groups, in particular to tackle resistant TB strains,” including investments for new vaccines. Europe has invested in TB research, but the EU and most MS are far behind their fair share targets. In fact, the majority barely cover half of their targets.³³

The EU’s AMR Accelerator | Innovative Medicines Initiative (AMR | IMI) invested the most in TB research in 2021: $31 million on TB drug development. While the AMR | IMI provides significant funding to TB drug development in support of the One Health Action Plan against AMR, it does not support TB vaccine research. The European Commission (EC) was the second-largest source of funds for TB research from the EU in 2021, at $30 million.³³ The EDCTP came in third, at €29 million. Both the EC and EDCTP fund TB vaccine research – $4.4 million and $5.8 million respectively in 2021.

We call on EU member states to substantially increase their investments in TB vaccine R&D in line with their fair share targets. This will advance the TB vaccine pipeline and enable new TB vaccines to be available as early as 2025, saving money, saving lives, and preventing massive economic losses.

Acknowledgements

This brief has been made possible by the work of Mike Frick¹, Karen Hoehn¹, Gwen Knight³, Jennifer Maple², Finn McQuaid³, Shaun Palmer², Maite Suarez², Nuno Viegas², Richard White³, and Jennifer Woolley⁴.

¹Treatment Action Group
²IAVI
³London School of Hygiene & Tropical Medicine
⁴Stop TB Partnership Working Group on New Vaccines

Follow #newTBvaccines on social media
Learn more at www.newtbvaccines.org/take-action
References


viii WHO. Tuberculosis Fact sheets. https://www.who.int/news-room/fact-sheets/detail/tuberculosis


xiii This average varies widely around the world. In some settings, such as Pakistan, it’s significantly higher. See, for example: Dodd PJ, Mafraikurev N, Seddon JA, McQuaid CF. (2022). The global impact of house hold contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study. The Lancet. VOLUME 10, ISSUE 7, E1034-E1044. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(22)00111-3/fulltext


xxxi This amount is separate to the European Commission contributions to AMR | IMI and EDCTP, which both also receive funding from other sources.

xxii WHO. Tuberculosis Profile: India. https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_fntity_type%3Dcountry%26entity%3D%26country%26iso2%3D%22IN%22 [Accessed 06 February 2023]